Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 2 1Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Neoplasms 10Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 6Carcinoma, Transitional Cell 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Carcinoma, Renal Cell 5Breast Neoplasms 4Triple Negative Breast Neoplasms 3Recurrence 3Melanoma 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Sarcoma 2Lymphoma, Follicular 2Lymphoma 2Central Nervous System Neoplasms 2Uveal Melanoma 1Urethral Neoplasms 1Ureteral Neoplasms 1Solid Tumors 1Skin Neoplasms 1Sezary Syndrome 1Prostatic Neoplasms 1Primary Myelofibrosis 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Mycosis Fungoides 1Metastatic Urothelial Cell Cancer 1Metastatic Solid Tumors 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 24Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × avelumab × Clear all
NCT03861403 2023-11-30

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Leap Therapeutics, Inc.

Phase 1 Terminated
10 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence

NCT03941262 2023-11-13

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

NKGen Biotech, Inc.

Phase 1 Completed
27 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT02603419 2020-04-24

JAVELIN HODGKINS

Pfizer

Phase 1 Terminated
34 enrolled 43 charts
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡